Risk analyses of N2 lymph-node metastases in patients with T1 non-small cell lung cancer: a multi-center real-world observational study in China

2019 ◽  
Vol 145 (11) ◽  
pp. 2771-2777
Author(s):  
Bing Chen ◽  
Wenjie Xia ◽  
Zhongqiu Wang ◽  
Heng Zhao ◽  
Xiaofei Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Observational Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Lymph Node Metastases ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastases

Chemical Anaplasia in Atypical Debut of Non-small Cell Lung Cancer with Inguinal and Obturator Lymph Node Metastases

2018 ◽  
Vol 69 (10) ◽  
pp. 2833-2836
Author(s):  
Laura Rebegea ◽  
Aurel Nechita ◽  
Cristina Serban ◽  
Camelia Diaconu ◽  
Luana Andreea Macovei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lymph Node Metastases ◽  
Palliative Chemotherapy ◽  
Small Cell ◽  
Lumbar Region ◽  
Small Cell Lung ◽  
Node Metastases

Non-small cell lung cancer (NSCLC) represents almost 80-85% of lung cancer cases. It is the most frequent malignancy after skin cancer. The therapeutic options for stage IV of disease consider histology, molecular characteristics, age, performance status, comorbidities, and not in the lust, patient�s option. This paper presents the case of a male patient, 73 years old, smoker, presented and treated in May 2016 in the Sf. Ap. Andrei Emergency Clinical Hospital Galati. The first sign of disease was inguinal and obturator right lymph node metastases whose histopathological test revealed metastases from malignant melanoma. Immunohistochemical tests (IHC) indicated undifferentiated carcinoma with lung as starting point, (Ck7 (+), TTF1 (+)). Thorax, abdominal and pelvic computed tomography (CT) imaging not evidenced space replacement processes in lung, but with mediastinal, right obturator and inguinal adenopathy. From personal pathological history we retain basocellular carcinoma in lumbar region, treated with surgery in 2009. It was initiated palliative chemotherapy and radiotherapy with remission of obturator and inguinal adenopathy, and at 9 months from diagnosis the Positron Emission Tomography (PET-CT) evidenced primary lung tumor situated in right superior lobe (RSL). At the present, patient is alive performing palliative chemotherapy. This case presented diagnostic and treatment issues, being a challenge for multidisciplinary team. We are mentioning the paucity of literature data regarding cases of primary tumors situated upper diaphragm which metastases in inguinal lymph nodes.

Overexpression of SLC1a5 in lymph node metastases outperforms assessment in the primary as a negative prognosticator in non-small cell lung cancer

Pathology ◽  
2018 ◽  
Vol 50 (3) ◽  
pp. 269-275 ◽  
Author(s):  
Agnes Csanadi ◽  
Annika Oser ◽  
Konrad Aumann ◽  
Vera Gumpp ◽  
Justyna Rawluk ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lymph Node Metastases ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastases

scholarly journals The Impact of Skip vs. Non-Skip N2 Lymph Node Metastasis on the Prognosis of Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Xinxin Wang ◽  
Haixie Guo ◽  
Quanteng Hu ◽  
Yongquan Ying ◽  
Baofu Chen
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lymph Node Metastases ◽  
Meta Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastases ◽  
The Impact

Objective: The skip N2 metastases were frequent in non-small-cell lung cancer (NSCLC) and the better prognosis of NSCLC with a skip over non-skip N2 lymph node metastases is controversial. The primary aim of this study is to investigate the prognosis effect of skip N2 lymph node metastases on the survival of NSCLC.Setting: A literature search was conducted in PubMed, EMBASE, and Cochrane Library with the term of “N2” or “mediastinal lymph node” or “mediastinal nodal metastases”, and “lung cancer” and “skip” or “skipping” in the title/abstract field. The primary outcomes of interests are 3- and 5-year survival in NSCLC.Participants: Patients who underwent complete resection by lobectomy, bilobectomy, or pneumonectomy with systemic ipsilateral lymphadenectomy and were staged as pathologically N2 were included.Primary and Secondary Outcome Measures: The 3- and 5-year survival of NSCLC was analyzed. The impact of publication year, number of patients, baseline mean age, gender, histology, adjuvant therapy, number of skip N2 stations, and survival analysis methods on the primary outcome were also analyzed.Results: A total of 21 of 409 studies with 6,806 patients met the inclusion criteria and were finally included for the analysis. The skip N2 lymph node metastases NSCLC had a significantly better overall survival (OS) than the non-skip N2 NSCLC [hazard ratio (HR), 0.71; 95% CI, 0.62–0.82; P < 0.001; I2 = 40.4%]. The skip N2 lymph node metastases NSCLC had significantly higher 3- and 5-year survival rates than the non-skip N2 lymph node metastases NSCLC (OR, 0.75; 95% CI, 0.66–0.84; P < 0.001; I2 = 60%; and OR, 0.78; 95% CI, 0.71–0.86; P < 0.001; I2 = 67.1%, respectively).Conclusion: This meta-analysis suggests that the prognosis of skip N2 lymph node metastases NSCLC is better than that of a non-skip N2 lymph node.

scholarly journals Prognostic significance of the pattern of pathological N1 lymph node metastases for non-small cell lung cancer

2019 ◽  
Vol 11 (8) ◽  
pp. 3449-3458
Author(s):  
Sergej Griff ◽  
Samantha Taber ◽  
Torsten T. Bauer ◽  
Joachim Pfannschmidt
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lymph Node Metastases ◽  
Prognostic Significance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastases

CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node Metastases

2009 ◽  
Vol 16 (12) ◽  
pp. 3473-3481 ◽  
Author(s):  
Kyoichi Kaira ◽  
Noboru Oriuchi ◽  
Hisao Imai ◽  
Kimihiro Shimizu ◽  
Noriko Yanagitani ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lymph Node Metastases ◽  
Poor Prognosis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastases

scholarly journals The Number of Lymph Node Metastases as a Prognostic Factor in Patients With N1 Non-small Cell Lung Cancer

CHEST Journal ◽  
2011 ◽  
Vol 140 (2) ◽  
pp. 433-440 ◽  
Author(s):  
Sirisha Jonnalagadda ◽  
Cardinale Smith ◽  
Grace Mhango ◽  
Juan P. Wisnivesky
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lymph Node Metastases ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastases

scholarly journals Clinical Analysis of N2 Patients with Skip Lymph Node Metastases in Non Small Cell Lung Cancer.

Haigan ◽  
1996 ◽  
Vol 36 (7) ◽  
pp. 893-898
Author(s):  
Eiji Yatsuyanagi ◽  
Satoshi Hirata ◽  
Hiroshi Moriyama ◽  
Susumu Koshiko ◽  
Yasukazu Sugimoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lymph Node Metastases ◽  
Clinical Analysis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Node Metastases

scholarly journals Development of a predictive radiomics model for lymph node metastases in pre-surgical CT-based stage IA non-small cell lung cancer

Lung Cancer ◽  
2020 ◽  
Vol 139 ◽  
pp. 73-79 ◽  
Author(s):  
Mengdi Cong ◽  
Hui Feng ◽  
Jia-Liang Ren ◽  
Qian Xu ◽  
Lining Cong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lymph Node Metastases ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Ia ◽  
Node Metastases
Sign in / Sign up

Export Citation Format

Share Document